Rizzari C, Santamaria M, Galli M A, Jankovic M, Uderzo C
Clinica Pediatrica dell'Università di Milano e Ospedale di Monza, Italia.
Pediatr Med Chir. 1987 Nov-Dec;9(6):749-50.
The authors report a case of fatal Daunorubicin cardiotoxicity on initial phase of therapy for Acute Myeloblastic Leukemia at cumulative doses (225 mg/mq) considered still safe from the current literature. Despite the interruption of therapy and the interventions performed in support of cardiac functionality the patient came to exitus for heart failure 24 hours after the symptoms onset. This example represents a further confirmation of the utility of a steady monitoring with specific tests for the patients undergoing Daunorubicin therapy.
作者报告了一例急性髓系白血病患者在初始治疗阶段发生柔红霉素心脏毒性致死的病例，其累积剂量（225mg/m²）从当前文献来看仍被认为是安全的。尽管中断了治疗并采取了支持心脏功能的干预措施，但患者在症状出现后24小时因心力衰竭死亡。这个例子进一步证实了对接受柔红霉素治疗的患者进行特定检查持续监测的实用性。
